Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: Results of a pilot study

Therapeutic Drug Monitoring

Volumn 32, Issue 2, 2010, Pages 152-158

  Åsberg, Anders ^a   Falck, Pål ^a   Undset, Liv H ^b   Dørje, Christina ^b   Holdaas, Hallvard ^b   Hartmann, Anders ^b   Midtvedt, Karsten ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bayesian; Cyclosporine; Dose prediction; Population pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID; PREDNISOLONE; CYCLOSPORIN;

ACCURACY; ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER SYSTEM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; COMPARATIVE STUDY; COMPUTER ASSISTED DRUG THERAPY; FOLLOW UP; GRAFT REJECTION; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; STANDARDS;

ADULT; AGED; CYCLOSPORINE; DRUG MONITORING; DRUG THERAPY, COMPUTER-ASSISTED; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 77950249133     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181d3f822     Document Type: Article

References (35)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605-612.
2. Opelz G, Dohler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation. 2009;87:795-802.
3. Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs. 2001;61:1957-2016.
4. Burdmann EA, Andoh TF, Yu L, et al. Cyclosporine nephrotoxicity. Semin Nephrol. 2003;23:465-476.
5. Nankivell, BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326-2333.
6. Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant. 2002;2:789-795.
7. Mourad M, Wallemacq P, De Meyer M, et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation. 2008;85(7 Suppl):S19-S24.
8. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4:378-383.
9. Bondareva IB, Sokolov AV, Tischenkova IF, et al. Population pharma-cokinetic modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: implications for dosage. J Clin Pharm Ther. 2001;26:213-223.
10. Bondareva IB, Jelliffe RW, Sokolov AV, et al. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. J Clin Pharm Ther. 2004; 29:105-120.
11. Goicoechea M, Vidal A, Capparelli E, et al. A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring. Antivir Ther. 2007;12:55-62.
12. Pea F, Bertolissi M, Di Silvestre A, et al. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Agents. 2002;20:326-332.
13. Fukudo M, Yano I, Shinsako K, et al. Prospective evaluation of the Bayesian method for individualizing tacrolimus dose early after living-donor liver transplantation. J Clin Pharmacol. 2009;49:789-797.
14. Wallin JE, Friberg LE, Fasth A, et al. Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. Ther Drug Monit. 2009;31:457-466.
15. Beal SL. NONMEM Users Guides. Ellicott City, MD: Icon Development Solutions; 1989-1998.
16. Irtan S, Saint-Marcoux F, Rousseau A, et al. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit. 2007;29:96-102.
17. Lukas JC, Suarez AM, Valverde MP, et al. Time-dependent pharmaco-kinetics of cyclosporine (Neoral) in de novo renal transplant patients. J Clin Pharm Ther. 2005;30:549-557.
18. Rousseau A, Leger F, Le Meur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit. 2004;26:23-30.
19. Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet. 2006;45:905-922.
20. Wu KH, Cui YM, Guo JF, et al. Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos. 2005;33:1268-1275.
21. Falck P, Midtvedt K, Van Le TT, et al. A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. Clin Pharmacokinet. 2009;48:615-623.
22. Katz DA, Grimm DR, Cassar SC, et al. CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther. 2004; 75:516-528.
23. Cremers SC, Scholten EM, Schoemaker RC, et al. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrol Dial Transplant. 2003;18:1201-1208.
24. Salas S, Mercier C, Ciccolini J, et al. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther Drug Monit. 2006;28:532-539.
25. Proost JH. Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Int J Clin Pharmacol Ther. 1995; 33:531-536.
26. Perner F, del Castillo D, Wauters JP, et al. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant. 2002;2:148-156.
27. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 1999;68:55-62.
28. Midtvedt K, Fauchald P, Bergan S, et al. C2 monitoring in maintenance renal transplant recipients: is it worthwhile? Transplantation. 2003;76: 1236-1238.
29. Stefoni S, Midtved K, Cole E, et al. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study. Transplantation. 2005;79:577-583.
30. Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation. 2003;76: 903-908.
31. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation. 2007;83:1525-1535.
32. Ekberg H, Mamelok RD, Pearson TC, et al. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. Transplantation. 2009;87:1360-1366.
33. Mendonza AE, Gohh RY, Akhlaghi F. Blood and plasma pharmacoki-netics of ciclosporin in diabetic kidney transplant recipients. Clin Pharmacokinet. 2008;47:733-742.
34. Hjelmesaeth J, Hagen LT, A° sberg A, et al. The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man. Nephrol Dial Transplant. 2007;22:1743-1749.
35. Pons JA, Ramirez P, Revilla-Nuin B, et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transplant. 2009;23:329-336.